Mark L. Tykocinski
Präsident bei Thomas Jefferson University
Aktive Positionen von Mark L. Tykocinski
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Thomas Jefferson University | Präsident | - | - |
Karriereverlauf von Mark L. Tykocinski
Ehemalige bekannte Positionen von Mark L. Tykocinski
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
American Society for Investigative Pathology
 American Society for Investigative Pathology BiotechnologyHealth Technology The American Society for Investigative Pathology operates as a biotechnology company. | Präsident | - | - |
| University of Pennsylvania | Corporate Officer/Principal | - | - |
| Sidney Kimmel Medical College | Corporate Officer/Principal | - | - |
| Thomas Jefferson University | Corporate Officer/Principal | - | - |
KAHR Medical Ltd.
 KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Technik-/Wissenschafts-/F&E-Leiter | 15.10.2009 | - |
| Gründer | 01.01.2005 | - |
Statistik
International
| Vereinigte Staaten | 5 |
| Israel | 2 |
Operativ
| Corporate Officer/Principal | 3 |
| President | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
American Society for Investigative Pathology
American Society for Investigative Pathology BiotechnologyHealth Technology The American Society for Investigative Pathology operates as a biotechnology company. | Health Technology |
- Börse
- Insiders
- Mark L. Tykocinski
- Erfahrung